IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

导出原文传递

翻译打印收藏纠错

作者： Rini, Brian I. ^[1] ; Stenzl, Arnulf ^[2] ; Zdrojowy, Romauld ^[3] ; Kogan, Mikhail ^[4] ; Shkolnik, Mikhail ^[5] ; Oudard, Stephane ^[6] ; Weikert, Steffen ^[7] ; Bracarda, Sergio ^[8] ; Crabb, Simon J. ^[9] ; Bedke, Jens ^[10] ; Ludwig, Joerg ^[11] ; Maurer, Dominik ; Mendrzyk, Regina ; Wagner, Claudia ; Mahr, Andrea ; Fritsche, Jens ; Weinschenk, Toni ; Walter, Steffen ; Kirner, Alexandra ; Singh-Jasuja, Harpreet ; Reinhardt, Carsten ; Eisen, Tim

作者单位： Immat Biotechnol, Tubingen, Germany ^[1] Vivantes Humboldt Clin, Berlin, Germany ^[2] Univ Cambridge, Cambridge, England ^[3] Univ Tubingen, Tubingen, Germany ^[4] Hop Europeen Georges Pompidou, Paris, France ^[5] Wroclaw Med Univ, Wroclaw, Poland ^[6] Univ Southampton, Southampton, Hants, England ^[7] Rostov State Med Univ Roszdrav, Rostov Na Donu, Russia ^[8] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44195 USA ^[9] Osped San Donato, Arezzo, Italy ^[10] Russian Sci Ctr Radiol & Surg Technol, St Petersburg, Russia ^[11]

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

The lancet oncology

2016年17卷11期

1599-1611页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

The lancet oncology

相似文献

The lancet oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial

The lancet oncology

相似文献

The lancet oncology

相关期刊

检索历史清除